Literature DB >> 23022311

Periventricular leukomalacia long-term prognosis may be improved by treatment with UDP-glucose, GDNF, and memantine in neonatal rats.

Feng-Xia Mao1, Wen-Juan Li, Hui-Jin Chen, Long-Hua Qian, Jeffrey S Buzby.   

Abstract

The therapeutic effects of UDP-glucose (UDPG), an endogenous agonist of GPR17 that may promote the self-repair of white matter, glial cell line-derived neurotrophic factor (GDNF), a neurotrophic factor correlated with the growth and survival of nerve cells, and memantine, an antagonist of NMDA receptors, were evaluated for functional improvement of neonatal rats with experimental periventricular leukomalacia (PVL). Five day-old neonatal rat pups were subjected to an ischemia-induced model of PVL. The pups were then randomly divided into sham, PVL, PVL plus UDPG, PVL plus GDNF, and PVL plus memantine groups. All pups were weighed and the age at first eye opening recorded. Pathological changes and myelin sheath formation in the white matter were assessed under both light and electron microscopy on day 7 and 21 after induction of PVL. Values of escape latency (EL) and swimming distance (SD) in Morris water maze test, and the modified inclined plane scores in Rivlin inclined plane test were recorded for rats on day 26. Pups in the PVL group were found to be significantly lower in weight (p<0.05), delayed in age at first eye opening (p<0.01), and impaired in their inclined plane (p<0.01) and Morris water maze (p<0.01) performance compared with those in the sham, UDPG, GDNF and memantine groups. Histopathological grading of the white matter classified all pups in the PVL group with significantly more severe injury (p<0.01), and the number and thickness of their myelin sheaths were significantly less (p<0.01), compared to the UDPG, GDNF, memantine, or sham groups. These results indicate that treatment with UDPG, GDNF, and memantine may significantly improve long-term prognosis in neonatal rats with cerebral white matter injury, characteristic of PVL.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23022311     DOI: 10.1016/j.brainres.2012.09.033

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

1.  Neovascularization and Synaptic Function Regulation with Memantine and Rosuvastatin in a Rat Model of Chronic Cerebral Hypoperfusion.

Authors:  Nan Zhang; Chenchen Song; Baomin Zhao; Mengya Xing; Lanlan Luo; Marc L Gordon; Yan Cheng
Journal:  J Mol Neurosci       Date:  2017-09-17       Impact factor: 3.444

2.  Expression of GPR17, a regulator of oligodendrocyte differentiation and maturation, in Nasu-Hakola disease brains.

Authors:  Jun-Ichi Satoh; Yoshihiro Kino; Motoaki Yanaizu; Youhei Tosaki; Kenji Sakai; Tusyoshi Ishida; Yuko Saito
Journal:  Intractable Rare Dis Res       Date:  2017-02

3.  Metformin Attenuates Cognitive Impairments in Hypoxia-Ischemia Neonatal Rats via Improving Remyelination.

Authors:  Boxiang Qi; Libao Hu; Lei Zhu; Lei Shang; Liping Sheng; Xuecheng Wang; Na Liu; Nana Wen; Xiaohe Yu; Qihong Wang; Yujia Yang
Journal:  Cell Mol Neurobiol       Date:  2016-12-29       Impact factor: 5.046

4.  Involvement of GPR17 in Neuronal Fibre Outgrowth.

Authors:  Max Braune; Nico Scherf; Claudia Heine; Katja Sygnecka; Thanigaimalai Pillaiyar; Chiara Parravicini; Bernd Heimrich; Maria P Abbracchio; Christa E Müller; Heike Franke
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

Review 5.  Pathophysiological Role of Purines and Pyrimidines in Neurodevelopment: Unveiling New Pharmacological Approaches to Congenital Brain Diseases.

Authors:  Marta Fumagalli; Davide Lecca; Maria P Abbracchio; Stefania Ceruti
Journal:  Front Pharmacol       Date:  2017-12-19       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.